WSGR logoWSGR logo
WSGR logo
  • Experience
  • People
  • Insights
  • About Us
  • Careers

  • Practice Areas
  • Industries

  • Corporate
  • Intellectual Property
  • Litigation
  • Patents and Innovations
  • Regulatory
  • Technology Transactions

  • Capital Markets
  • Corporate Governance
  • Corporate Life Sciences
  • Derivatives
  • Emerging Companies and Venture Capital
  • Employee Benefits and Compensation
  • Energy and Climate Solutions
  • Executive Advisory Program
  • Finance and Structured Finance
  • Fund Formation
  • Greater China
  • Mergers & Acquisitions
  • Private Equity
  • Public Company Representation
  • Real Estate
  • Restructuring
  • Shareholder Engagement and Activism
  • Tax
  • U.S. Expansion
  • Wealthtech

  • Special Purpose Acquisition Companies (SPACs)

  • Environmental, Social, and Governance

  • AI and Data Center Infrastructure
  • Energy Regulation and Competition
  • Project Development and M&A
  • Project Finance and Tax Credit Transactions
  • Sustainability and Decarbonization
  • Transportation Electrification

  • U.S. Expansion Library and Resources

  • Post-Grant Review
  • Trademark and Advertising

  • Antitrust Litigation
  • Arbitration
  • Board and Internal Investigations
  • Class Action Litigation
  • Commercial Litigation
  • Consumer Litigation
  • Corporate Governance Litigation
  • Employment Litigation
  • Executive Branch Updates
  • Government Investigations
  • Internet Strategy and Litigation
  • Patent Litigation
  • Securities Litigation
  • State Attorneys General
  • Supreme Court and Appellate Practice
  • Trade Secret Litigation
  • Trademark and Copyright Litigation
  • Trial
  • White Collar Crime

  • Advertising, Promotions, and Marketing
  • Antitrust and Competition
  • Committee on Foreign Investment in the U.S. (CFIUS)
  • Communications
  • Data, Privacy, and Cybersecurity
  • Export Control and Sanctions
  • FCPA and Anti-Corruption
  • FDA Regulatory, Healthcare, and Consumer Products
  • Federal Trade Commission
  • Fintech and Financial Services
  • Government Contracts
  • National Security and Trade
  • Payments
  • State Attorneys General
  • Strategic Risk and Crisis Management
  • Tariffs, Customs, and Import Compliance

  • Antitrust and Intellectual Property
  • Antitrust Civil Enforcement
  • Antitrust Compliance and Business Strategy
  • Antitrust Criminal Enforcement
  • Antitrust Litigation
  • Antitrust Merger Clearance
  • European Competition Law
  • Third-Party Merger and Non-Merger Antitrust Representation

  • Anti-Money Laundering
  • Foreign Ownership, Control, or Influence (FOCI)
  • Team Telecom

  • AI in Healthcare
  • Animal Health
  • Artificial Intelligence and Machine Learning
  • Aviation
  • Biotech
  • Blockchain and Cryptocurrency
  • Clean Energy
  • Climate and Clean Technologies
  • Communications and Networking
  • Consumer Products and Services
  • Data Storage and Cloud
  • Defense Tech
  • Diagnostics, Life Science Tools, and Deep Tech
  • Digital Health
  • Digital Media and Entertainment
  • Electronic Gaming
  • Fintech and Financial Services
  • FoodTech and AgTech
  • Global Generics
  • Internet
  • Life Sciences
  • Medical Devices
  • Mobile Devices
  • Mobility
  • NewSpace
  • Quantum Computing
  • Semiconductors
  • Software

  • Offices
  • Country Desks
  • Events
  • Community
  • Our Diversity
  • Sustainability
  • Our Values
  • Board of Directors
  • Management Team

  • Austin
  • Boston
  • Boulder
  • Brussels
  • Century City
  • Hong Kong
  • London
  • Los Angeles
  • New York
  • Palo Alto
  • Salt Lake City
  • San Diego
  • San Francisco
  • Seattle
  • Shanghai
  • Washington, D.C.
  • Wilmington, DE

  • Law Students
  • Judicial Clerks
  • Experienced Attorneys
  • Patent Agents
  • Business Professionals
  • Alternative Legal Careers
  • Contact Recruiting
Alexandra Stebbins
Associate
Corporate
Boston
Austin
astebbins@wsgr.com

D617-598-7893

Download vCard
Open PDF

Alexandra (Alex) Stebbins is an associate for the Boston office of Wilson Sonsini Goodrich & Rosati, where she is a member of the corporate group and focuses on emerging companies in the life sciences industry.

During law school, Alex focused on transactional topics, particularly business law and negotiations.

Prior to law school, Alex was a field artillery officer in the U.S. Army, stationed throughout the United States, South Korea, Kuwait, and Afghanistan.

Alex is working remotely from the firm’s Austin office. 

Experience

Alexandra (Alex) Stebbins is an associate for the Boston office of Wilson Sonsini Goodrich & Rosati, where she is a member of the corporate group and focuses on emerging companies in the life sciences industry.

During law school, Alex focused on transactional topics, particularly business law and negotiations.

Prior to law school, Alex was a field artillery officer in the U.S. Army, stationed throughout the United States, South Korea, Kuwait, and Afghanistan.

Alex is working remotely from the firm’s Austin office. 

Education
  • J.D., Harvard Law School, 2024

    Cum Laude; Board of Student Advisers; Chair, Ames Moot Court Competition

  • B.A., Public Policy, Duke University, 2014
Admissions
  • State Bar of Massachusetts
  • State Bar of Texas
Credentials
Education
  • J.D., Harvard Law School, 2024

    Cum Laude; Board of Student Advisers; Chair, Ames Moot Court Competition

  • B.A., Public Policy, Duke University, 2014
Admissions
  • State Bar of Massachusetts
  • State Bar of Texas
Focus Areas
  • Corporate
  • Corporate Governance
  • Life Sciences
  • Mergers & Acquisitions
Recent Insights
Client Highlights
Wilson Sonsini Advises NexCure on $19 Million Series A Financing
On March 5, 2026, NexCure, a healthcare company with a mission to deliver CAR-T and other clinically intensive treatments in community-based outpatient settings, launched with a $19 million Series A financing. The financing was led by RA Capital Management, with participation from Cencora Ventures and Oncology Ventures. Wilson Sonsini Goodrich & Rosati advised NexCure on the transaction.
Learn More
Client Highlights
Wilson Sonsini Advises Cognito Therapeutics on Oversubscribed $105 Million Series C
On March 5, 2026, Cognito Therapeutics, a late clinical-stage neurotechnology company pioneering non-invasive neuroprotective therapies in neurodegenerative diseases, announced the closing of an oversubscribed $105 million Series C financing round. Wilson Sonsini Goodrich & Rosati advised Cognito Therapeutics on the transaction.
Learn More
View All
  • people
  • insights
  • about us
  • careers
  • Binder
  • Alumni
  • Mailing List Signup
  • Client FTP Portal
  • Privacy Policy
  • Terms of Use
  • Accessibility
WSGR logo
Twitter
LinkedIn
Facebook
Instagram
Youtube
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.